Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
about
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in SpainPredictors of de novo urge urinary incontinence after photoselective vaporization of the prostate.Rates of self-reported urinary, gastrointestinal, and pain comorbidities in women with vulvar lichen sclerosus.Purinergic signalling in the urinary tract in health and disease.
P2860
Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacotherapy of overactive ...... siology of overactive bladder.
@en
Pharmacotherapy of overactive ...... siology of overactive bladder.
@nl
type
label
Pharmacotherapy of overactive ...... siology of overactive bladder.
@en
Pharmacotherapy of overactive ...... siology of overactive bladder.
@nl
prefLabel
Pharmacotherapy of overactive ...... siology of overactive bladder.
@en
Pharmacotherapy of overactive ...... siology of overactive bladder.
@nl
P2860
P921
P1476
Pharmacotherapy of overactive ...... siology of overactive bladder.
@en
P2093
Antonella Giannantoni
Jerilyn M Latini
P2860
P304
P356
10.1517/14656566.2011.554396
P407
P577
2011-02-26T00:00:00Z